Current Report Filing (8-k)
February 22 2019 - 11:46AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported):
February 22, 2018
Heyu Biological Technology Corporation
(Exact Name of Registrant as Specified in its
Charter)
Nevada
|
|
000-26731
|
|
87-0627910
|
(State or Other Jurisdiction of
Incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification Number)
|
4th Floor, No. 10 Building, Xinglin Bay Business
Operation Center,
Jimei District, Xiamen City,
Fujian Province, China 361022
(Address of Principal Executive Offices, Zip
Code)
Registrant’s telephone number, including
area code:
(86) 158 5924 0902
Check the appropriate box below if the Form
8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by
check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 8.01 Other Events
On February 22, 2019, the Board of Directors
of Heyu Biological Technology Corporation (the “Company”) decided that the Company would focus on the production and
sale in China of medical equipment designed to fight cancer. The Company is cooperating with a research team led by Professor Yu
Xu, a researcher in the treatment of cancer, to produce and sell their Submillimeter Wave (Terahertz) Quantized Space Therapy Chamber,
which is a new product based on submillimeter wave theory of therapy. The Company is finalizing the design of this new product
and is in the process of seeking government approval for its production and sale in China.
Forward-Looking Statements
This Current Report on Form 8-K includes
statements that may constitute “forward-looking” statements, usually containing the words “believe,” “estimate,”
“project,” “anticipate,” “expect,” or similar expressions. Forward-looking statements inherently
involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements.
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the Company has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.
|
Heyu Biological Technology Corporation
|
|
|
|
|
By:
|
/s/
Ban Siong Ang
|
|
Name:
|
Ban Siong Ang
|
|
Title:
|
Chief Executive Officer
|
|
|
|
|
Dated:
|
February 22, 2019
|
Heyu Biological Technology (PK) (USOTC:HYBT)
Historical Stock Chart
From Aug 2024 to Sep 2024
Heyu Biological Technology (PK) (USOTC:HYBT)
Historical Stock Chart
From Sep 2023 to Sep 2024